Posts

Posted on

Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors

GAITHERSBURG, Md., Dec. 09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Margaret G. McGlynn, R. Ph. to its board as an independent director. Ms. McGlynn brings extensive pharmaceutical industry, vaccine and non-profit experience to her role on the Novavax Board of Directors.

“Margie’s deep experience in vaccine commercialization and understanding of global public health will be invaluable as we move closer to collecting Phase 3 clinical data and submitting NVX-CoV2373, our COVID-19 vaccine candidate, for regulatory authorization and approval,” said Stanley C. Erck, Novavax President and Chief Executive Officer.

Ms. McGlynn is currently President and Board Chair for HCU Network America, an advocacy organization she founded in 2016 that is dedicated to supporting the needs of those impacted by the rare genetic condition homocystinuria (HCU) and related disorders. Prior to founding HCU Network America, Ms. McGlynn served as President and Chief Executive Officer of the International AIDS Vaccine Initiative (IAVI), where she led extensive partnership efforts to advance the development, global launch and access to a broadly effective HIV vaccine. She previously spent more than two decades at Merck, where she held roles of increasing responsibility, including President of Merck Vaccines and Infectious Diseases, and President, U.S. Hospital and Specialty Products Division.

“This is a very exciting time to be joining the Novavax Board, and I look forward to working with my fellow directors to support Novavax’ critical priority to advance and deploy NVX-CoV2373 globally to help end this devastating pandemic, as well as progress the broader vaccine portfolio,” said Ms. McGlynn.

She currently serves on the boards of directors of Amicus Therapeutics and Vertex Pharmaceuticals. In addition to her corporate experience, Ms. McGlynn has served as a Board member for several non-profit organizations, including Hilleman Institute for Developing World Vaccine Research, Gavi, the Vaccine Alliance, the Biotechnology Innovation Organization (BIO), and Life Science Cares Philadelphia.

Ms. McGlynn holds a Bachelor of Science degree in pharmacy, a Master of Business Administration in marketing, and an honorary doctorate from the State University of New York at Buffalo.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The Company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Novavax Forward Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, and Quarterly Report on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.



Contacts:         
Investors
Erika Trahan
[email protected]
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
[email protected]
617-974-8659

Posted on

Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria

HAMPTON, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria (CIndU). CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. As previously presented, CDX-0159 demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, indicative of systemic mast cell ablation in a Phase 1a single dose, healthy volunteer study. In October, Celldex also announced the initiation of a Phase 1b study in chronic spontaneous urticaria.

“Inducible urticarias can significantly impact a patient’s quality of life, including insomnia, lack of energy, poor self-image, social withdrawal and depression,” said Dr. Marcus Maurer, Professor of Dermatology and Allergy and Director of Research at the Department of Dermatology and Allergy at the Allergie-Centrum-Charité of the Charité – Universitätsmedizin in Berlin and the lead investigator for the study. “This is especially true for cold contact urticaria and symptomatic dermographism as avoiding the triggers for these diseases is extremely difficult and therapies that address the root cause of disease—mast cell activation—are sorely needed. We look forward to completing this study and believe CDX-0159 could be a much needed disease-modifying drug for these patients.”

“With the initiation of our second study in urticaria, Celldex has laid an exciting foundation for the CDX-0159 program,” said Diane C. Young, MD, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. “The CIndU study should provide rapid clinical proof of concept in a disease setting that is clearly driven by mast cells. In addition to continuing to assess the safety and potential clinical benefit of CDX-0159, we also hope to confirm its impact on mast cells through the collection and analysis of serial skin biopsies, answering an important question about CDX-0159’s mechanism of action.”

The Phase 1b study is an open label clinical trial designed to evaluate the safety of a single dose of CDX-0159 in up to 20 patients with cold contact urticaria (n=10) or symptomatic dermographism (n=10) who are refractory to antihistamines. Patients’ symptoms will be induced via provocation testing that resembles real life triggering situations. Secondary and exploratory objectives include pharmacokinetic and pharmacodynamic assessments, including changes from baseline provocation thresholds, measurement of tryptase and stem cell factor levels, clinical activity outcomes (impact on urticaria symptoms, disease control, clinical response), quality of life assessments and measurement of tissue mast cells through skin biopsies. CDX-0159 will be administered intravenously (3.0 mg/kg) as add on treatment to H1-antihistamines. More information about this study is available on www.clinicaltrials.gov (Identifier: NCT04548869). Initial data from the study are expected at the end of the first quarter of 2021.

CIndUs are forms of urticaria that have an attributable cause or trigger associated with them, typically resulting in hives or wheals. Approximately 0.5% of the total population suffers from inducible urticarias. Celldex is exploring the two most common forms, cold-induced and dermographism (scratch-induced) urticarias. People afflicted with cold induced urticaria experience symptoms like itching, burning wheals and angioedema where their skin comes in contact with temperatures below skin temperature. Symptomatic dermographism is characterized by the development of a wheal and flare reaction in response to a stroking, scratching or rubbing of the skin, usually occurring within minutes of the inciting stimulus. For both of these diseases, mast cell activation leading to release of soluble mediators is thought to be the driving mechanism leading to the wheals and other symptoms. There are currently no approved therapies for CIndUs and patients attempt to manage symptoms associated with their disease through avoidance of triggers and the use of antihistamines. Celldex believes that CDX-0159 has significant potential to directly inhibit and/or ablate mast cells which, in turn, could be disease modifying for patients.

About CDX-
0159

CDX-0159 is a monoclonal antibody that binds the KIT receptor with high specificity and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. Celldex is currently studying CDX-0159 in chronic urticarias. Currently approved therapies for chronic urticarias target symptomatic relief. Celldex believes that CDX-0159 has significant potential to interfere with mast cells at multiple steps upstream of current treatments, which, in turn, could be disease modifying for patients. In addition, Celldex is also evaluating additional opportunities in other mast cell driven diseases where CDX-0159’s potency and high specificity for KIT could be important.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Forward Looking Statement

This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates; the effects of the outbreak of COVID-19 on our business and results of operations; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the cost of paying development, regulatory approval and sales-based milestones under our merger agreement with Kolltan, including the cost, timing, and outcome of our declaratory judgment action against the Kolltan stockholder representative with respect to certain of those milestones; the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company’s programs to continue to develop; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under “Risk Factors” in our annual report on Form 10-K and quarterly reports on Form 10-Q.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact

Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
Celldex Therapeutics, Inc.
(781) 433-3161
[email protected]



Posted on

Orbital Energy Group Regains Nasdaq Compliance

PR Newswire

HOUSTON, Dec. 9, 2020 /PRNewswire/ — Orbital Energy Group, Inc. (NASDAQ: OEG) (“Orbital Energy” or the “Company”), today announced that it received official notification from The NASDAQ Stock Market that the Company has regained compliance with the minimum bid price requirement for continued listing on the NASDAQ Capital Market.

On December 8, 2020, NASDAQ provided confirmation that for the last 11 consecutive business days, from November 20th to December 7th, 2020, the closing bid price of Orbital Energy’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5550(a)(2) and this matter is now closed.

About Orbital Energy Group

Orbital Energy Group, Inc. (NASDAQ: OEG), formerly known as CUI Global, Inc., is creating a diversified energy services platform through the acquisition and development of innovative companies. Orbital Energy’s group of businesses includes: Orbital Gas Systems, Inc., Orbital Power Services and Orbital Solar Services. Orbital Gas Systems is a 30-year leader in innovative gas solutions, serving the energy, power and processing markets through the design, installation and commissioning of industrial gas sampling, measurement and delivery systems. Orbital Power Services provides engineering, construction, maintenance and emergency response solutions to the power, utilities and midstream markets. Orbital Solar Services provides engineering, procurement and construction (“EPC”) expertise in the renewable energy industry and established relationships with solar developers and panel manufacturers in the utility scale solar market. As a publicly traded company, Orbital Energy is dedicated to maximizing shareholder value. But most important, our commitment to conduct business with a high level of integrity, respect, and philanthropic dedication allows the organization to make a difference in the lives of their customers, employees, investors and global community.

For more information please visit: www.orbitalenergygroup.com 

Important Cautions Regarding Forward Looking Statements

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The Company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, our reliance on third-party manufacturers and suppliers, government agency budgetary and political constraints, new or increased competition, changes in market demand, and the performance or reliability of our products. These factors and others could cause operating results to vary significantly from those in prior periods, and those projected in forward-looking statements. Additional information regarding these and other factors, which could materially affect the Company and its operations, are included in certain forms the Company has filed with the Securities and Exchange Commission.

Investor Relations:
KCSA Strategic Communications
David Hanover
T: 212-896-1220
[email protected]   

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/orbital-energy-group-regains-nasdaq-compliance-301189260.html

SOURCE Orbital Energy Group, Inc.

Posted on

IBM Launches New Innovative Capabilities for Watson; Leading Global Brands including EY and Regions Bank use Watson to Infuse Intelligence into Workflows

– IBM Research innovations in natural language processing, automation and building trust to be commercialized in Watson products

PR Newswire

NEW YORK, Dec. 9, 2020 /PRNewswire/ — IBM (NYSE: IBM) today announced innovative new capabilities planned for IBM Watson designed to help scale the use of AI by businesses.

Developed by IBM Research, the new capabilities are designed to improve the automation of AI, provide a higher degree of precision in natural language processing, and foster greater trust in outcomes derived from AI predictions. They include:

  • Reading Comprehension is based on an innovative question-answering (QA) system from IBM Research. Currently in beta in IBM Watson Discovery, it is planned as a new feature that can help identify more precise answers in response to natural language queries from vast troves of complex enterprise documents. It also provides scores that indicate how confident the system is in each answer.
  • FAQ Extraction uses a novel NLP technique from IBM Research to automate the extraction of Q&A pairs from FAQ documents. Currently in beta in IBM Watson Assistant‘s search skill, it is planned as a new feature to help businesses keep virtual assistants up-to date with the latest answers and reduce the time-consuming process of manual updates.
  • A new intent classification model is now available in IBM Watson Assistant. It is designed to more accurately understand an end-user’s goal or intent when engaging with a virtual assistant and to enable administrators to train the system faster. The model provides more accurate results from less data versus compared commercial systems1. This can help businesses go live with virtual assistants in a few days while achieving high accuracy.
  • IBM Watson Discovery now includes support for 10 new languages including Bosnian, Croatian, Danish, Finnish, Hebrew, Hindi, Norwegian (Bokmål), Norwegian (Nynorsk), Serbian and Swedish. IBM has continued to add support for additional languages to help businesses build global, enterprise-grade NLP solutions.

Read more about the natural language processing updates here. 

“This past year has shown us that the real power of AI is in helping companies take action and respond to changing conditions in real time. That means in minutes and hours — not weeks or months,” said Daniel Hernandez, General Manager of Data and AI, IBM. “Today’s new AI capabilities are yet another example of how cutting-edge AI advancements coming out of IBM Research help us to deliver innovations for language, automation and building trust in IBM Watson that are changing the game for businesses of all sizes and across all industries.”

Advancing AI Governance Capabilities to Help Build Trust and Transparency in Business Outcomes

IBM also announced plans to commercialize IBM Research-developed ‘AI Factsheets’ in Watson Studio in Cloud Pak for Data throughout the next year. Like nutrition labels for foods or information sheets for appliances, AI Factsheets are designed to provide information about a product’s important characteristics. Standardizing and publicizing this information will help build trust in AI services across the industry.

To complement this, IBM Services for AI at Scale, a new consulting offering, provides businesses with a framework, methodology, and underlying technology to guide organizations on their journey to  trustworthy and ethical AI. IBM Cloud Pak for Data also has new capabilities to provide a complete foundation for AI that can run on any cloud. Read more about the AI Governance updates here.

Leading global brands are using IBM Watson to infuse intelligence into their workflows. For instance, a global leader in assurance, tax, strategy and transactions and consulting services, EY is transforming the M&A due diligence process using IBM Watson Discovery. Following the expansion of its global alliance with IBM earlier this summer, EY launched Diligence Edge, which includes a custom NLP model trained on EY proprietary M&A language, to help deal makers identify and leverage valuable insights throughout the transaction’s lifecycle, as well as make informed decisions on deal value opportunities to gain an advantage in competitive deal processes.

Regions Bank has worked with IBM to complete a model monitoring use case that leverages IBM Cloud Pak for Data and Watson OpenScale. Regions was able to have a continuous read on model accuracy in production and achieved a higher confidence in the quality of predictions. IBM provides a standardized and disciplined approach to tracking model performance and will further Regions’ end-to end model lifecycle management program. The company is also using IBM Watson to enhance customer service and reports having decreased call wait times by 40 percent since the start of the COVID-19 pandemic using Watson Assistant.

EY and Regions Bank join a growing list of companies using IBM Watson, including Japan Airlines,  NatWest, Maricopa County  and many more. 

Today’s news is another step from IBM to advance its AI for business strategy: from commercializing advanced NLP capabilities from Project Debater; expanding its AI-powered automation capabilities with the launch of IBM Watson AIOps, acquisitions of WDG Automation and Instana2 and expanded ecosystem partnerships including ServiceNow; and helping businesses, healthcare organizations, governments and academic institutions use IBM Watson Assistant to get information they deem trustworthy on the pandemic to stakeholders.

For more information on today’s announcement, please visit: https://newsroom.ibm.com/new-innovative-capabilities-for-watson

[1] Qi et. al, 2020: Benchmarking Intent Detection for Task-Oriented Dialog Systems https://arxiv.org/pdf/2012.03929.pdf

[2] Expected to close within several weeks.

About IBM Watson

Watson is IBM’s AI technology for business, helping organizations to better predict and shape future outcomes, automate complex processes, and optimize employees’ time. Watson has evolved from an IBM Research project, to experimentation, to a scaled, open set of products that run anywhere. With more than 30,000 client engagements, Watson is being applied by leading global brands across a variety of industries to transform how people work. To learn more, visit: https://www.ibm.com/watson.


Forward-Looking and Cautionary Statements

IBM’s statements regarding its plans, directions, and intent are subject to change or withdrawal without notice at IBM’s sole discretion.   Information regarding potential future products is intended to outline our general product direction and it should not be relied on in making a purchasing decision. The information mentioned regarding potential future products is not a commitment, promise, or legal obligation to deliver any material, code or functionality. Information about potential future products may not be incorporated into any contract. The development, release, and timing of any future features or functionality described for our products remains at our sole discretion.

Contact:

Zachery Bishop

IBM Media Relations
[email protected]

Sarah Murphy

IBM Media Relations
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ibm-launches-new-innovative-capabilities-for-watson-leading-global-brands-including-ey-and-regions-bank-use-watson-to-infuse-intelligence-into-workflows-301189360.html

SOURCE IBM

Posted on

4Front Ventures to Open Mission Dispensary in Calumet City, Illinois

PR Newswire

Second Illinois retail location will open on Tuesday, December 15 at 9AM CT with a grand ceremony

PHOENIX, Dec. 9, 2020 /PRNewswire/ — 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (“4Front” or the “Company”) continues to focus its efforts in the Illinois market and is pleased to announce that it will open its second Mission Dispensary in Calumet City, IL on December 15th. This new 3,000- square-foot facility located at 1330 Torrence Avenue, is about 20 miles south of Chicago and the closest dispensary to the Indiana state line.

4Front previously announced that it received its special use permit on July 22nd for an additional retail location in Calumet, IL. Shortly thereafter, Cannabis Facility Construction (CFC) broke ground and began the build of the space. On December 15th at 9am CT, Mission Calumet City will host a socially distant, grand-opening ceremony which will include a tour of the dispensary for special guests and appearances by Mission/4Front executives to mark this momentous occasion. The doors will open to the public at large at 10 am.

“The opening of Mission Calumet City is another significant milestone for the Company and a testament to our commitment to the Illinois community. It is important for us to demonstrate that we are fully committed to being a contributing member of the community, adding to economic development during a difficult time,” said 4Front and Mission President Kris Krane. “This expansion into Calumet City was a natural next step as we aim to provide access to cannabis products. We are excited to launch here and look forward to becoming a staple in the community and meeting the needs of our customers.” 

The grand opening ceremony at Mission Calumet City will be held on Tuesday December 15th at 9 a.m. CT featuring community members and local officials.

Following the grand opening, Mission Calumet City will officially open its doors to customers at 10 a.m. CT while following all social distance protocols as recommended by the CDC.

To receive company updates and be added to the email distribution list please sign up here.

About 4Front Ventures Corp.

4Front (CSE: FFNT) (OTCQX: FFNTF) is a national multi-state cannabis operator and retailer, with a market advantage in mass-produced, low-cost quality branded cannabis products. 4Front manufactures and distributes a portfolio of over 25 cannabis brands including Marmas, Crystal Clear, Funky Monkey, Pebbles, and the Pure Ratios wellness collection, distributed through retail outlets and their chain of strategically positioned Mission branded dispensaries.

Headquartered in Phoenix, Arizona, 4Front has operations in Illinois, Massachusetts, California, Michigan and Washington state. From plant genetics to the cannabis retail experience, 4Front’s team applies expertise across the entire cannabis value chain. For more information, visit 4Front’s website www.4frontventures.com.

4Front Investor Contacts

Andrew Thut, Chief Investment Officer
[email protected] 
602-633-3067

Phil Carlson / Elizabeth Barker
[email protected]
212-896-1233 / 212-896-1203

4Front Media Contacts

Anne Donohoe / Nick Opich
KCSA Strategic Communications
[email protected] / [email protected] 
212-896-1265 / 212-896-1206

This news release was prepared by management of 4Front Ventures, which takes full responsibility for its contents. The Canadian Securities Exchange (“CSE”) has not reviewed and does not accept responsibility for the adequacy of this news release. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in 4Front Ventures’ periodic filings with securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to future developments and the business and operations of 4Front Ventures, developments with respect to legislative developments in the United States, expectations regarding the COVID-19 pandemic, future revenue or Adjusted EBITDA expectations, statements regarding when or if any contemplated or in-progress transactions will close or if/when required regulatory approvals are attained, and other statements regarding future developments of the business. The closing of the transactions described in this news release, including the divesture of Pennsylvania and Maryland assets and the sale of convertible debt, is subject to customary conditions and there can be no guarantee that such transactions will close.

Although 4Front Ventures has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under U.S. federal laws; change in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. 4Front Ventures disclaims any intention or obligation to update or revise such information, except as required by applicable law, and 4Front Ventures does not assume any liability for disclosure relating to any other company mentioned herein.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/4front-ventures-to-open-mission-dispensary-in-calumet-city-illinois-301189266.html

SOURCE 4Front

Posted on

Texas Instruments makes high-reliability products immediately available for purchase on TI.com

TI opens its inventory of thousands of space-grade and military-grade products to help aerospace and defense electronics companies meet growing demand

PR Newswire

DALLAS, Dec. 9, 2020 /PRNewswire/ — Texas Instruments (TI) (Nasdaq: TXN) today announced that it is making most of its high-reliability (HiRel) semiconductor products immediately available for online purchase on TI.com, helping aerospace and defense companies quickly get the authentic TI products they need for their next-generation space-grade and military-grade designs. For more information, visit www.ti.com/TIHiRel-pr.

Engineers and purchasing managers can now access TI’s inventory of thousands of HiRel products on TI.com, including radiation-hardened and radiation-tolerant products in the qualified manufacturers list (QML) plastic, ceramic or metallic packages used in space, avionics and defense system designs. Additionally, purchasers now have multiple options to select date and lot codes before placing an order.

“Increasingly, customers are developing highly sophisticated satellites and other advanced electronics that must operate in harsh conditions, and our customers expect shorter supplier lead times to meet mission-critical project timelines,” said Gary Reichmuth, general manager for aerospace and defense systems at Texas Instruments. “With the vast inventory of our HiRel products available on TI.com, supported with lot selection options and associated documentation, customers will be able to obtain HiRel products and get to production faster than with other semiconductor suppliers.”

TI’s long history in aerospace and defense electronics

For over 60 years, TI integrated circuits have been used in many spacecraft and defense electronics in the United States, Europe and other regions. TI has a long track record of manufacturing HiRel products, helping assure a steady supply of parts to customers who develop space, commercial and military applications. More than half of TI’s manufacturing sites are QML-certified, enabling the company to quickly qualify, manufacture and ship high-quality, reliable analog and embedded processing products.

Product innovation

Two of TI’s newest HiRel space products include DC/DC buck converters intended to help customers meet key power management challenges of different satellite mission profiles. The TPS7H4001-SP provides industry-leading power density for full QML-V, radiation-hardness-assured satellite applications, and the TPS7H4010-SEP offers the widest voltage range for the shorter missions of low-earth-orbit satellites.

In addition to power management, aerospace companies can purchase other TI devices on TI.com, such as the LMX2615-SP 40-MHz to 15-GHz wideband radio frequency synthesizer with phase synchronization and the new LMK04832-SP ultra-low noise clock jitter cleaner. Both of these clock and timing devices support the Joint Electron Device Engineering Council (JEDEC) JESD204B standard and help to reduce design complexity and weight, while increasing system stability in satellite systems.

Instant access to QML ceramic package material information

Traditionally, one of the biggest barriers to obtaining QML-V and QML-Q products has been access to material content information for ceramic packaging before purchasing those products. To help solve this challenge, TI has added a quality, reliability and packaging data download feature on TI.com to obtain detailed ceramic package material information for up to 100 parts at once, as well as details about restriction of hazardous substances (RoHS); registration, evaluation, authorization and restriction of chemicals (REACH); and green status.

New TI HiRel product ordering features available on TI.com

TI offers the following specific features to simplify aerospace and defense manufacturers’ purchasing experience at any stage, from concept to production:

  • Immediately available inventory
    : Customers can select from thousands of authentic TI HiRel products to get their space-grade and military-grade systems to market quickly.
  • Multiple date and lot-code options: New options on TI.com enable users to select specific date and lot codes as needed before placing an order. Each QML lot ships with a certificate of conformance – a quality conformance inspection and a processing conformance report summarizing traceability and testing performed – per Military Performance Specification (MIL-PRF)-38535.
  • Multiple payment options
    : TI continues to make it more convenient for companies to purchase and obtain authentic TI products at the lowest online price.* Customers can now easily transact on TI.com in U.S. dollars (USD), euros (EUR), British pounds (GBP) and other currencies. TI also offers a line of credit in USD or EUR through Apruve.
  • Fast, reliable shipping: Whether companies need to order a single part or multiple HiRel product quantities, TI simplifies delivery by handling the logistics and importation process in select countries, making it easier for customers to get the products they need.

About Texas Instruments

Texas Instruments Incorporated (Nasdaq: TXN) manufactures, tests and sells analog and embedded processing chips for markets such as industrial, automotive, personal electronics, communications equipment and enterprise systems. Our passion to create a better world by making electronics more affordable through semiconductors is alive today, as each generation of innovation builds upon the last to make our technology smaller, more efficient, more reliable and more affordable – making it possible for semiconductors to go into electronics everywhere. We think of this as Engineering Progress. It’s what we do and have been doing for decades. Learn more at TI.com.

Trademarks

The TI logo and other designated brands included herein are trademarks of Texas Instruments Incorporated. All other trademarks belong to their respective owners.

*Lowest online prices on 1,000-unit quantities for 99% of TI’s immediately available inventory. Excludes expired products and products sold by nonauthorized sources.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/texas-instruments-makes-high-reliability-products-immediately-available-for-purchase-on-ticom-301189258.html

SOURCE Texas Instruments

Posted on

Luokung cooperates with Yiting to provide location-based commercial marketing services for more than 90,000 gas stations across China.

PR Newswire

BEIJING, Dec. 9, 2020 /PRNewswire/ — Luokung Technology Corp. (NASDAQ: LKCO) (“Luokung” or the “Company”), one of the global leading spatial-temporal big-data processing technology companies, a leading interactive location-based services company in China, today announced that it has signed an agreement with Guangdong Yiting Information Technology Co., Ltd. (“Yiting”). The two parties will cooperate to provide location-based commercial marketing services for more than 90,000 gas stations across China. Relying on the ecological cooperation system between Yiting and Gas Stations and the Luokung map open platform, this cooperation enables each gas station to manage its own features on the map, including but not limited to personalized landmarks, personalized navigation routes, real-time map updates and display of marketing information for gas related and non-gas related products on the site, and other personalized marketing services. With the capability of completing all relevant transactions on the map, it enables gas stations as an example of “my position that I operate in my way”.

Guangdong Yiting Information Technology Co., Ltd. is a leading service provider of senseless and contactless payment in China’s energy retail industry. Cooperating with China UnionPay, Agricultural Bank of China, China Construction Bank, Industrial and Commercial Bank of China, PetroChina, Sinopec, Sinochem, etc, it deploys a senseless payment system in gas stations,  and launches services including refueling through Electric Toll Collection (“ETC”), one-key refueling and non-gas related products, which covers more than 100 million drivers, 93,000 gas stations, by collaborating with China’s leading mobile gas platform and smart gas station service platform, such as Guanghui Cloud Oil, Tuan Oil, Easy Fuel, Xiaoju Refuel, Didi Refuel, Feeding Car and Smart Fueler etc.

About Luokung Technology Corp.

Luokung Technology Corp. is one of the global leading spatial-temporal big-data processing technology companies and a leading interactive location-based services company in China. It provides integrated DaaS, SaaS, and PaaS services for Internet and Internet of Things of Spatial-Temporal big data based on its patented technology. Based on geographic information systems and intelligent Spatial-Temporal big data, it establishes city-level and industry-level digital twin holographic data models to actively serve smart cities, intelligent transportation, smart industry, LBS. http://www.luokung.com

Business Risks and Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

CONTACT:
The Company:
Mr. Jay Yu 
Chief Financial Officer
Tel:  +86-10-5327-4727
Email: [email protected]

INVESTOR RELATIONS
PureRock Communications Limited
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/luokung-cooperates-with-yiting-to-provide-location-based-commercial-marketing-services-for-more-than-90-000-gas-stations-across-china-301189092.html

SOURCE Luokung Technology Corp.

Posted on

Avast Identifies APT Group Targeting Government Agencies in East Asia

The research indicates that the APT group LuckyMouse could be behind the attack, and was found using new and advanced tactics to access sensitive government data

PR Newswire

PRAGUE, Dec. 9, 2020 /PRNewswire/ — Avast (LSE:AVST), a global leader in digital security and privacy products, has identified a new advanced persistent threats (APT) campaign targeting government agencies and a government data center in Mongolia.

Avast Threat Intelligence researchers found that the APT group planted backdoors and keyloggers to gain long-term access to government networks belonging to the government of Mongolia. Avast researchers consider LuckyMouse, also known as EmissaryPanda and APT27, is likely to be behind the APT campaign. The group, which has previously attacked targets in the area, is well-known for going after national resources and political information on near neighbors.

Following research and analysis, Avast researchers noticed the group has updated their tactics. For this attack, the group used both keyloggers and backdoors to upload a variety of tools that they used to scan the target network and dump credentials. They used this to access sensitive government data.

The tactics used by the APT group to access the infrastructure of government institutions  include accessing a vulnerable company who were providing services to the government, and through a malicious email attachment that was using weaponized documents via an unpatched CVE-2017-11882 vulnerability.

“The APT group Lucky Mouse has been active since Autumn 2017 and has been able to avoid Avast attention in the last two years due to their evolving techniques and marked change of tactics. We were able to detect their new tactics to discover this campaign targeting the Mongolian government, showing how they’ve scaled their operations to be more advanced to gain longer term access to sensitive data,” says Luigino Camastra, malware researcher at Avast.

A detailed technical summary can be found on the Avast Threat Intelligence blog Decoded.

About Avast:

Avast (LSE: AVST), a FTSE 100 company, is a global leader in digital security and privacy products. With over 435 million users online, Avast offers products under the Avast and AVG brands that protect people from threats on the internet and the evolving IoT threat landscape. The company’s threat detection network is among the most advanced in the world, using machine learning and artificial intelligence technologies to detect and stop threats in real time. Avast digital security products for Mobile, PC or Mac are top-ranked and certified by VB100, AV-Comparatives, AV-Test, SE Labs and others. Visit: www.avast.com

Media contact:

[email protected] 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/avast-identifies-apt-group-targeting-government-agencies-in-east-asia-301189220.html

SOURCE Avast

Posted on

PTC Therapeutics to Host Translarna™ Deep Dive Webinar

PR Newswire

SOUTH PLAINFIELD, N.J., Dec. 9, 2020 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing Translarna on Tuesday, December 15 at 12:00 noon ET.

The Translarna Deep Dive will provide an overview of results from the clinical and real-world data generated to date for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in patients 2 years and older. PTC will also review Translarna’s commercial success and the potential regulatory milestones in the United States.  As a reminder, the results from Study PTC124-GD-045-DMD will be available in the first quarter of 2021.

The webinar can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the webinar and providing the passcode 9694665. A live, listen-only webcast can be accessed on the Events and Presentations page under the investor relations section of PTC Therapeutics’ website at www.ptcbio.com. A webcast replay will be available approximately two hours after completion of the webinar and will be archived for 30 days following the webinar.

About Duchenne muscular dystrophy

Primarily affecting males, Duchenne muscular dystrophy (Duchenne) is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure. It is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of all muscles, including skeletal, diaphragm, and heart muscles. Patients with Duchenne can lose the ability to walk (loss of ambulation) as early as age ten, followed by loss of the use of their arms. Duchenne patients subsequently experience life-threatening lung complications, requiring the need for ventilation support, and heart complications in their late teens and twenties.

More information regarding Duchenne is available through the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy. Additionally, information and resources are available at www.duchenneandyou.com. 

About Translarna™ (ataluren)

Translarna (ataluren), discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. Translarna, the tradename of ataluren, is licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged two years and older. Ataluren is an investigational new drug in the United States.

About PTC Therapeutics, Inc.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.


FOR MORE INFORMATION PLEASE CONTACT:


Media:


Investors:

Jane Baj

Lisa Hayes

+1 (908) 912-9167

+1 (732) 354-8687


[email protected]  


[email protected]  

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, PTC’s strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words “guidance”, “plan,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions.

PTC’s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those factors discussed in the “Risk Factors” section of PTC’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC’s other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna.

The forward-looking statements contained herein represent PTC’s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

 

Cision View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-host-translarna-deep-dive-webinar-301189290.html

SOURCE PTC Therapeutics, Inc.

Posted on

PayPal Processed More than $185 Million in Donations this GivingTuesday in A Year Unlike Any Other

More than Two Million Donations Made on the PayPal Platform to Over 163,000 Nonprofits and Causes Around the Globe

PR Newswire

SAN JOSE, Calif., Dec. 9, 2020 /PRNewswire/ — PayPal Holdings, Inc. (NASDAQ: PYPL) today announced that it processed a record-breaking $185 million globally this GivingTuesday, the largest amount raised on the platform for the global day of giving since its inception in 2012. With a 40 percent increase in donations processed over 2019, more than 1.75 million PayPal customers across 198 markets donated to causes they care about, amounting to over two million donations in total. 

With the giving season underway, more than half of charitable organizations in the U.S. expect to raise less money than they did in 2019, as a result of the financial strain experienced by people and businesses across the country since the start of the pandemic.1 To help offset this pressure on charities, PayPal has provided its customers with a robust Giving platform, that allows customers to give back throughout the year in a number of ways, from donating with the PayPal Giving Fund to contributing micro-donations or donating with credit card rewards at online retailers that accept PayPal at checkout.

“We are moved and inspired by the generosity of our PayPal community, as millions of our customers turn to our platform to give to the causes they care about,” said Franz Paasche, SVP, Corporate Affairs, PayPal. “Despite the considerable challenges of this year, our customers and communities joined together to give back when it matters most, contributing more than they ever have in the history of GivingTuesday. We’re proud that PayPal’s platform is enabling the generosity of people around the world as they contribute and support this movement.” 

PayPal is one of the largest digital donation platforms in the world, supporting more than 600,000 nonprofits with fundraising. Every year, PayPal joins with its community of more than 350 million consumers and merchants to contribute to charitable efforts across the globe, and participate in campaigns with partners like GivingTuesday, which PayPal has supported since the movement began in 2012.

This year, PayPal also announced enhancements to its Giving platform to give its customer community even more ways to give back and support the causes they care about, with the introduction of the Generosity Network. The PayPal giving platform places the power of fundraising in customers’ hands, enabling them to create campaigns to raise money for the people, causes and communities they care about – be it a small business, a friend or family member, or a nonprofit – and connects each campaign with millions of people who can help to give what they can. Inspired by the rise in popularity of peer-to-peer crowdfunding amidst the pandemic, the Generosity Network provides customers with a way to give and get help throughout the holiday season and beyond.

About PayPal
PayPal has remained at the forefront of the digital payment revolution for more than 20 years. By leveraging technology to make financial services and commerce more convenient, affordable, and secure, the PayPal platform is empowering more than 350 million consumers and merchants in more than 200 markets to join and thrive in the global economy. For more information, visit paypal.com.


1 According to a 2020 survey conducted by the Association of Fundraising Professionals.

Media Relations Contact

Jaymie Sinlao

[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/paypal-processed-more-than-185-million-in-donations-this-givingtuesday-in-a-year-unlike-any-other-301189394.html

SOURCE PayPal Holdings, Inc.